28.29
+0.09
+(0.32%)
At close: April 17 at 8:00:14 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Cash Flows from Used in Operating Activities Direct
2,769,000
--
--
--
--
Operating Cash Flow
2,768,986
2,768,986
2,987,802
2,143,980
2,017,536
Investing Cash Flow
-2,678,115
-2,678,115
-2,072,789
-1,029,421
-1,870,280
Financing Cash Flow
361,145
361,145
-2,148,754
-944,856
385,112
End Cash Position
929,026
929,026
477,010
1,710,751
1,541,048
Issuance of Debt
1,471,235
1,471,235
350,000
--
1,272,533
Repayment of Debt
--
--
-1,350,000
--
--
Repurchase of Capital Stock
-229,651
-229,651
-304,759
--
--
Free Cash Flow
2,768,986
2,768,986
2,987,802
2,143,980
2,017,536
12/31/2021 - 8/18/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
05Y.MU Vivoryon Therapeutics NV
1.7140
0.00%
ARDX.MX Ardelyx, Inc.
105.50
0.00%
P0F.F Egetis Therapeutics AB (publ)
0.2835
-2.58%
BT3.BE Lineage Cell Therapeutics Inc
0.3600
-1.10%
MVR0.BE Medivir AB
0.1372
-2.42%
2HA.F Spero Therapeutics, Inc.
0.6340
+0.16%
HQ1.MU Oruka Therapeutics Inc. R
7.50
+2.04%
DBV.F DBV Technologies S.A.
1.2520
+1.79%
PROT Proteonomix, Inc.
0.0000
0.00%
HTD.MU Corcept Therapeutics Inc
57.90
-3.60%